Journal of Clinical Oncology· 2019Q1
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
- 1,060citations
- Q1SCImago
- 2019year
Short summary
Pembrolizumab monotherapy achieved a 12.2% objective response rate (ORR) in 98 previously treated patients with advanced cervical cancer, with all responses occurring in PD-L1-positive tumors.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Obstetrics and Gynecology
Obstetrics and GynecologyMedicine